The United Arab Emirates has registered Sinopharm as the official vaccine to be used to vaccinate the citizens of the country on Wednesday.

After successfully conducting phase three trials for China's Sinopharm, the vaccine was approved by the UAE authorities. It is found to have86 percent efficacy rate. The Ministry of the Health has also released a statement saying that the approval of the vaccine is a “major step towards combating the global pandemic”.

The Ministry and Department of Health Abu Dhabi also carried out an analysis which showed that the vaccine has a 100 percent effectiveness rate that helps in “preventing moderate and severe cases of the disease" and other than that it also has 99 percent ‘reconversion rate’ that deal with the antibodies built up in the body.

The phase three trial for the inactivated vaccine was conducted for a long time in the UAE where the summer campaign involved nearly 31,000 people. The vaccine was created by a research group based out of China called Beijing Institute of Biological Products along with Sinopharm, which is one of the biggest drug makers in China.

Earlier in the month of september, the vaccine was granted a nod for its emergency use i the country under which the focus group included the frontline workers, healthcare staff, government health officials, emergency service personnel, and a number of Cabinet ministers which also included Sheikh Mohammed bin Rashid, Vice President and Ruler of Dubai.

Even after the approval of the COVID-19 vaccine, the authorities are careful about the usage and have started a post-authorization safety and efficacy study of everything that was found in the phase three trials. A statement released by the officials read, “These ongoing studies show similar safety and efficacy profiles as the interim analysis.”

The ministry also affirmed that the official registration of the Sinopharm vaccine will help protect the population of the UAE and will allow us to open our economy. The vaccine is yet to disclose the finding and data after the phase three trial but the data which was published by the UAE is the first time that some detail about the vaccine’s effectiveness was given.

The maintenance criteria for the Sinopharm vaccine is also not as hectic as it is for Moderna and Pfizer-BioNTech vaccine. These two vaccines require freezing storage while Sinopharm can be easily stored in regular refrigerators making it easy for them to be transmitted for long distances. Countries are already gearing up for its use. Morocco for instance has already ordered 10 million doses while Egypt, Bahrain, Peru and Argentina are conducting phase three trial.